Article
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
Clinical lung cancer - 1 Nov 2021
Riess Jonathan W, Reckamp Karen L, Frankel Paul, Longmate Jeffrey, Kelly Karen A, Gandara David R, Weipert Caroline M, Raymond Victoria M, Keer Harold N, Mack Philip C, Newman Edward M, Lara Primo N
Abstract excerpt
BACKGROUND: Onalespib is a novel heat shock protein 90 inhibitor (HSP90i). Previous preclinical and clinical studies with HSP90i have demonstrated activity in EGFR-mutant non-small cell lung cancer (NSCLC). This study sought to determine the safety and tolerability of onalespib plus erlotinib in EGFR-mutant NSCLC and to evaluate the preliminary efficacy of the combination in epidermal growth factor receptor exon...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.